基于基因分型的 #mCRPC 靶向治疗：BARCODE2 试验结果。由 Ann-Britt Jones 博士在 #ESMO26 上报告，@zklaassen_md 撰写报道 > https://bit.ly/47B7thq #ProstateCancer #PrecisionOncology @myESMO
362 浏览 · 3 赞 · 3 转发 · 1 回复
Distinguishing clonal hematopoiesis (CH) from tumor homologous recombination repair (HRR) alterations in liquid biopsy: Implications for PARP inhibitor (PARPi) use in metastatic castration-resistant prostate cancer (mCRPC)
https://esmocongress.esmo.orgPlasma ctDNA as standalone or adjunct to tumour tissue for HRR and PI3K/AKT genotyping in mCRPC: PROMPT (NCT04746300)
https://esmocongress.esmo.org- sciqst@sciqst
@urotoday @zklaassen_md @myESMO The key distinction is prognostic versus predictive value: a genomic signal may correlate with outcomes without showing which treatment will work best. Explore that broader evidence with a biomedical literature review at https://sciqst.com.
来源：UroToday.com · x.com